Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.
Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market l...
– Priority Review recognizes the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new t...
Renewed partnership combines best in class engineering capabilities with cutting edge science to accelerate the availability ...
U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medi...
The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the s...
– The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-fr...
Roche's Genentech reported results from the Phase 1b trial of CT-388 for obesity and type 2 diabetes. The 24-week study sho...
Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant ...
